Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …

PURPOSE Patients with advanced endometrial carcinoma have limited treatment options.
We report final primary efficacy analysis results for a patient cohort with advanced …

PURPOSE Modulation of vascular endothelial growth factor–mediated immune suppression
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …

Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …

Background & Aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-
related deaths worldwide, but there is a deficiency of early diagnosis biomarkers and …

Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but
prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and …

Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors. We …

Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low
five-year survival rates leading to a substantial worldwide burden for healthcare systems …